

Synthesis of N^1 - and N^8 -(γ -L-Glutamyl)spermidines and (γ -L-Glutamyl)putrescine

Kazuya Toho¹, Naoki Abe^{*1}, Teiko Yamada², Yoshifumi Ito^{#,1}, Hiroyuki Konno³, Shigefumi Kuwahara² and Hiromasa Kiyota^{*,2}

¹Lab. of Applied Microbiology; ²Lab. of Applied Bioorganic Chemistry, Graduate School of Agricultural Science, Tohoku University, Aoba-ku, Sendai, 981-8555 Japan; ³Department of Chemistry and Chemical Engineering, Graduate School of Science and Engineering, Yamagata University, Jonan, Yonezawa 992-8510, Japan

Received January 19, 2010; Revised June 02, 2010; Accepted June 14, 2010

Abstract: (γ -L-Glutamyl)putrescine and N^1 - and N^8 -(γ -L-glutamyl)spermidines, possible regioisomeric products of the polyamine glutamyl transferase of bacteria such as *Escherichia coli* and *Pseudomonas aeruginosa*, were synthesized from *N*-Boc-protected putrescine and 1,3-propanediamine.

Keywords: glutamylspermidine, glutamylputrescine, *Pseudomonas aeruginosa*, polyamine biosynthesis, polyamine glutamyl transferase.

INTRODUCTION

Polyamines (spermine, spermidine, putrescine etc.) are a group of ubiquitous polycations necessary for optimal cell growth of prokaryotic and eukaryotic cells [1], and thus it is important to elucidate their metabolic pathways. Recently, γ -glutamylolation was found to be a key reaction in the metabolism. N^1 -(γ -L-Glutamyl)spermidine (**1**, Fig. 1) and N^8 -(γ -L-glutamyl)spermidine (**2**), plausible metabolic intermediates, were firstly reported by Folk as unnatural compounds prepared by enzymatic procedure [2]. Later, (γ -L-glutamyl)spermidine conjugates were identified *in vitro* as a major protein secreted from the rat seminal vesicles [3]. Folk *et al.* also showed their ion-exchange chromatogram using HPLC method [2, 4]. γ -L-Glutamylputrescine (**3**), one of the key compounds in polyamine metabolism, was found in mammalian brain [5], and recently in *Escherichia coli* K-12 [6, 7]. We report here the synthesis and spectroscopic data of three γ -L-glutamylated polyamines (**1**, **2** and **3**) as standards for the metabolic studies.

RESULTS AND DISCUSSION

The synthesis of the compounds is shown in Scheme 1. Recently, Jeitner *et al.* reported the synthesis of HCl salts of **1** and **3** in a similar manner as we describe here [8]. The free N^1 amino group of N^4, N^8 -bis(Boc)-spermidine (**4**) [9, 10] was condensed with *N*-Boc-*O*-*t*-Bu-L-glutamic acid (**5**) [11] using water-soluble carbodiimide (EDCI) in 55% yield to give **6** [8]. Finally, acidic deprotection of the three Boc and one *t*-Bu group afforded **1**. Similarly, N^8 -(γ -L-glutamyl)spermidine

(**2**) and (γ -L-glutamyl)putrescine (**3**) were prepared from N^1, N^8 -bis(Boc)-spermidine (**7**) [12] and *N*-Boc-putrescine (**9**) [13], respectively. Most of the ^1H and ^{13}C NMR resonances (Table 1) of the target compounds were assigned by the HH-COSY, HMQC and HMBC spectra. Positions of each amide bond were confirmed by the observation of ^1H - ^{13}C three bond correlations from H(1) to C(5') for **1** and from H(8) to C(5') for **2** in the HMBC spectra.




Fig. (1). N^1 - and N^8 - γ -L-glutamylspermidines, and (γ -L-glutamyl)putrescine.

EXPERIMENTAL


General

Optical rotation: *Horiba Sepa-300* apparatus. FT-IR: *Jasco 4100* apparatus (ATR, Zn-Se); in cm^{-1} . ^1H and ^{13}C NMR: *Varian Inova 600* (600 MHz for ^1H and 150 MHz for ^{13}C) and *Inova 500* apparatuses (500 MHz for ^1H and 126 MHz for ^{13}C); rel. to Me_4Si ($= 0$ ppm). Mass spectra: *Jeol JMS-700*; in m/z .

*Address correspondence to these authors at the Lab. of Applied Bioorganic Chemistry, Graduate School of Agricultural Science, Tohoku University, Aoba-ku, Sendai, 981-8555 Japan; Tel/Fax: +81-22-717-8785; E-mail: kiyota@biochem.tohoku.ac.jp

Lab. of Applied Microbiology, Graduate School of Agricultural Science, Tohoku University, Aoba-ku, Sendai, 981-8555 Japan; Tel: +81-22-717-8781; Fax: +81-22-717-8780; ; E-mail: nabe@biochem.tohoku.ac.jp

#The late.



Scheme 1. Synthesis of N^1 - and N^8 - γ -L-glutamylspermidines, and (γ -L-glutamyl)putrescine.

a) N -Boc- O - t -Bu-L-Glu (5), EDCI, CH_2Cl_2 . **b)** $\text{CF}_3\text{CO}_2\text{H}$, CH_2Cl_2 , 0°C .

Table 1. ^1H and ^{13}C NMR Spectral Data of 1, 2 and 3 (600 MHz for ^1H and 150 MHz for ^{13}C in D_2O)

No	1			2			3		
	^1H	mult. (Hz)	^{13}C	^1H	mult. (Hz)	^{13}C	^1H	mult. (Hz)	^{13}C
1	3.21	t (6.5)	36.26	3.09*	t (7.8)	36.65	3.20	t (6.5)	38.78
2	1.82	quint (7.3)	25.99*	2.03	quint (7.3)	23.81	1.56	quint (7.0)	25.47
3	2.98	m	45.23	3.04*	t (8.7)	45.54	1.65	quint (7.3)	24.26
4							2.98	t (7.3)	39.22
5	2.99	m	47.03	3.02	t (8.1)	47.46			
6	1.690	m	22.86	1.64	quint (7.3)	25.50			
7	1.679	m	23.99	1.52	quint (7.3)	23.07			
8	2.97	m	38.88	3.16	t (6.9)	38.69			
1'	-		171.49	-		171.45	-		171.82*
2'	4.03	t (6.5)	52.30	4.04	t (6.6)	52.54	4.04	m	52.62
3'	2.13	dt (15.0, 7.2)	25.65*	2.14	dt (15.0, 7.3)	25.78	2.19	m	25.89
	2.17	dt (15.0, 6.6)		2.19	dt (15.0, 7.3)				
4'	2.40	dt (15.5, 7.6)	31.11	2.41	dt (15.3, 7.6)	31.24	2.46	m	31.32
	2.44	dt (15.5, 7.3)		2.44	dt (15.5, 7.6)		-		
5'	-		174.56	-		174.19	-		174.24*
NH	7.57	br							
	8.14								
	8.30								
	10.8								

Unable to redefine the ambiguous assignments (*) due to the overlapping and/or lack of the key HMBC/HMQC correlation.

N^4, N^8 -Bis(*tert*-butoxycarbonyl)- N^1 -(*N*-*tert*-butoxycarbonyl-O-*tert*-butyl- γ -L-glutamyl)spermidine (6) [8]

To a solution of amine **4** (FW: 345.48, 80 mg, 0.22 mmol), **5** (FW: 303.35, 64 mg, 0.21 mmol) and *i*-Pr₂NEt (FW: 129.24, 39 mg, 0.23 mmol) in dry CH₂Cl₂ (2 ml) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI·HCl, FW: 191.71, 50 mg, 0.26 mmol) at 0°C and the mixture was stirred at room temp. for 12 h. Then the mixture was diluted with EtOAc, washed three times with water, dried with MgSO₄ and concd. *in vacuo*. The residue was chromatographed on silica gel (CHCl₃/MeOH = 100:1) to give **6** (FW: 630.81, 78 mg, 0.12 mmol, 55%) as a colorless oil, $[\alpha]_D^{22} +1.6^\circ$ (c 3.9, CHCl₃). *R*_f 0.40 (CHCl₃/MeOH = 20:1). IR: 3350*m* (N–H), 1699*s* (C=O), 1679*s* (C=O), 1366*s*, 1258*s*, 1152*s*, 749*vs*. ¹H NMR (CDCl₃, 500 MHz) δ : 1.44 (s, 2 x *t*-Bu), 1.454 (s, *t*-Bu), 1.462 (s, *t*-Bu), 1.4–1.6 (*m*, CH₂(6, 7)), 1.65 (*br s*, CH₂(2)), 1.91 (*br s*, 1 H-(3')), 2.15 (*m*, 1 H-(3')), 2.27 (*m*, CH₂(4')), 3.12 & 3.14 (*br s*, CH₂(5, 8)), 3.20 (*br s*, CH₂(1)), 3.26 (*br s*, CH₂(3)), 4.14 (*br s*, 1 H, H-(2')), 4.57 (*br*, 0.75 H, H-(N⁸)), 4.68 (*br*, 0.25 H-(N⁸)), 5.27 (*pseudo d*, *J* = 7.3, H-(NCHC₂)), 6.41 (*br*, 0.75 H -(N¹)), 6.89 (*br*, 0.75 H-(N¹)). ¹³C NMR (CDCl₃, 126 MHz) δ : 27.9, 28.3, 28.4, 32.7, 35.7, 40.0, 43.3, 46.6, 53.6, 53.8, 79.1, 79.7, 81.9, 82.2, 155.6, 155.9, 171.5, 172.0. FAB-MS: 631 ($[M+H]^+$), 531 ($[M+2H-t-BuOC=O]^+$), 475, 275. HR-FAB-MS: 631.4286 ($[M+H]^+$, C₃₁H₅₉O₉N₄; calc. 631.4282).

 N^1 -(γ -L-Glutamyl)spermidine (1)

A solution of **6** (FW: 630.81, 70 mg, 0.11 mmol) in CF₃CO₂H (2.8 ml) and CH₂Cl₂ (1.7 ml) was stirred at 40°C for 12 h. Then the mixture was concd. *in vacuo* and the residue was chromatographed on silica gel (CHCl₃/MeOH/aq. NH₃ = 2:2:1) to give **1** (FW: 274.36, 38 mg, 0.12 mmol, quant.) as a colorless oil, $[\alpha]_D^{22} +6.1^\circ$ (c 1.3, MeOH). *R*_f 0.05 (CHCl₃/MeOH/aq. NH₃ = 2:2:1). IR: 3330*m*, (N–H), 3190*m* (N–H), 2958*s*, 1696*m*, (C=O), 1625*s* (C=O), 1235*m*, 1153*w*. FAB-MS: 297 ($[M+Na]^+$), 275 ($[M+H]^+$), 180, 153, 135, 115, 72, 61. HR-FAB-MS: 275.2080 ($[M+H]^+$, C₁₂H₂₇O₃N₄; calc. 275.2083).

 N^1, N^4 -Bis(*tert*-butoxycarbonyl)- N^8 -(*N*-*tert*-butoxycarbonyl-O-*tert*-butyl- γ -L-glutamyl)spermidine (8)

In a similar manner as described for **6**, **7** (FW: 345.48, 205 mg, 0.593 mmol) was converted to **8** (FW: 630.81, 151 mg, 0.239 mmol, 40.3%) as a colorless oil, $[\alpha]_D^{27} +1.7^\circ$ (c 1.1, CHCl₃). *R*_f 0.40 (CHCl₃/MeOH = 20:1). IR: 3330*m* (N–H), 1692*vs* (C=O), 1678*vs* (C=O), 1365*s*, 1249*s*, 1151*vs*, 752*vs*. ¹H NMR (CDCl₃, 500 MHz) δ : 1.438 (s, *t*-Bu), 1.443 (s, *t*-Bu), 1.461 (s, 2 x *t*-Bu), 1.50 (*m*, 2 H), 1.56 (*m*, 2 H), 1.65 (*br s*, 2 H), 1.95 (*br s*, 1 H), 2.15 (*m*, 1 H), 2.26 (*t*, *J* = 6.8, 2 H), 3.10 (*br s*, 2 H), 3.6 (*m*, 2 H), 3.18–3.31 (*m*, 4 H), 4.13 (*br s*, 1 H-(2')), 4.82 (*br s*, 0.5 H), 5.27 (*br d*, *J* = 6.8, 1 H), 5.32 (*br s*, 0.5 H), 6.43 (*br s*, 0.5 H), 6.54 (*br s*, 0.5 H). ¹³C NMR (CDCl₃, 126 MHz) δ : 28.0, 28.3, 28.5, 32.8, 37.4, 37.7, 39.2, 43.7, 44.3, 46.1, 46.6, 53.4, 78.9, 79.2, 79.6, 79.9, 80.0, 82.2, 82.4, 155.6, 156.0, 156.2, 171.4, 172.2. FAB-MS: 631 ($[M+H]^+$), 531 ($[M+2H-t-BuOC=O]^+$), 475, 275. HR-FAB-MS: 631.4282 ($[M+H]^+$, C₃₁H₅₉O₉N₄; calc. 631.4282).

 N^8 -(γ -L-Glutamyl)spermidine (2)

In a similar manner as described for **1**, **8** (112 mg, 0.178 mmol) was converted to **2** (FW: 274.36, 46.0 mg, 0.168 mmol, 94%) as a colorless oil, $[\alpha]_D^{27} +3.0^\circ$ (c 1.1, MeOH). *R*_f 0.05 (CHCl₃/MeOH/aq. NH₃ = 2:2:1). IR: 3384*s* (N–H), 2948*s*, 1736*m* (C=O), 1634*m* (C=O), 1210*m*, 1048*m*. FAB-MS: 273 ($[M-H]^-$), 195, 155, 127, 97. HR-FAB-MS: 273.1925 ($[M-H]^-$, C₁₂H₂₅O₃N₄; calc. 273.1927).

 N^4 -(*tert*-Butoxycarbonyl)- N^1 -(*N*-*tert*-butoxycarbonyl-O-*tert*-butyl- γ -L-glutamyl)putrescine (10)

In a similar manner as described for **6**, **9** (FW: 188.27, 80 mg, 0.43 mmol) was converted to **10** (FW: 473.60, 71 mg, 0.15 mmol, 35%) as a colorless oil, $[\alpha]_D^{27} +1.2^\circ$ (c 0.70, CHCl₃). *R*_f 0.54 (CHCl₃/MeOH = 20:1). IR: 3341*m* (N–H), 2977*m*, 2934*m*, 1698*s* (C=O), 1652*m* (C=O), 1524*m*, 1366*m*, 1251*s*, 1172*s*. ¹H NMR (CDCl₃, 500 MHz) δ : 1.44 (s, *t*-Bu), 1.45 (s, *t*-Bu), 1.46 (s, *t*-Bu), 1.54 (*m*, CH₂(2, 3)), 1.85 (*m*, 1 H-(3')), 2.15 (*m*, 1 H-(3')), 2.25 (*t*, *J* = 7.1, CH₂(4')), 3.14 (*br s*, CH₂(NH)), 3.28 (*m*, CH₂(NH)), 4.14 (*m*, 1 H-(N)), 4.65 (*br s*, 1 H-(N)), 5.25 (*d*, *J* = 8.0, 1 H-(2')), 6.43 (*br s*, 1 H-(N)). FAB-MS: 474 ($[M+H]^+$), 374 ($[M+2H-(t-BuOC=O)]^+$), 318 ($[M+3H-(t-BuOC=O)-t-Bu]^+$), 262, 244, 218 ($[M+4H-2(t-BuOC=O)-t-Bu]^+$). HR-FAB-MS: 474.3186 ($[M+H]^+$, C₂₃H₄₄O₇N₃; calc. 474.3179).

 N -(γ -L-Glutamyl)putrescine (3)

In a similar manner as described for **1**, **10** (70 mg, 0.15 mmol) was converted to **3** (FW: 217.27, 38 mg, 0.12 mmol, 55%) as an amorphous solid, $[\alpha]_D^{28} +4.62^\circ$ (c 2.25, MeOH). *R*_f 0.3 (CHCl₃/MeOH/aq. NH₃ = 2:2:1). IR: 3330*m* (N–H), 3190*br vs* (O–H), 1736*m* (C=O), 1634*s* (C=O), 1561*m*, 1509*m*, 1399*s* (C–O), 1228*w*, 1160*w*, 1048*w*. FAB-MS (in D₂O): 225 ($[M-6H+7D]^+$) 176, 156, 154, 138, 136, 108, 89, 78; (in H₂O): 216 ($[M-H]^+$), 188, 151. HR-FAB-MS: 225.1952 (in D₂O, $[M-6H+7D]^+$, C₉H₁₃D₇O₃N₃; calc. 225.1944), 216.1347 (in H₂O, $[M-H]^+$, C₉H₁₈O₃N₃; calc. 216.1348).

ACKNOWLEDGEMENT

We appreciate the financial supported from the Grant-in-aid from Japan Society for the Promotion of Science (19580120).

REFERENCES

- [1] Glansdorff, N. In: *Escherichia coli and Salmonella. Cellular and Molecular Biology*; Neidhardt, F. C., Ed.; Am. Soc. Microbiol., Washington, DC, **1996**, pp. 408–433.
- [2] Folk, J.E. Synthesis of N^1 -(γ -glutamyl)spermidine, N^8 -(γ -glutamyl)spermidine, N^1, N^8 -bis(γ -glutamyl)spermidine, N^1 -(γ -glutamyl)spermine, N^1, N^{12} -bis(γ -glutamyl)spermine, and N^1, N^4 -bis(γ -glutamyl)putrescine. *Methods Enzymol.*, **1983**, 94, 451–457.
- [3] Porta, R.; Esposito, C.; Metafora, S.; Malorni, A.; Pucci P.; Marino, G. Purification and structural characterization of *in vitro* synthesized (γ -glutamyl)spermidine conjugates of a major protein secreted from the rat seminal vesicles. *Adv. Exp. Med. Biol.*, **1988**, 250, 403–409.
- [4] Beninati, S.; Martinet, N.; Fold, J.E. High-performance liquid chromatographic method for the determination of ϵ -(γ -glutamyl)lysine and mono- and bis- γ -glutamyl derivatives of putrescine and spermidine. *J. Chromatog.*, **1988**, 443, 329–335.

- [5] Nakajima, T.; Kakimoto, Y.; Tsuji, M.; Konishi, H. Occurrence and formation of γ -glutamylputrescine in mammalian brain. *J. Neurochem.*, **1976**, 26, 115-118.
- [6] Kurihara, S.; Oda, S.; Kato, K.; Kim, H.-G.; Koyanagi, T.; Kumagai, H.; Suzuki, H. A novel putrescine utilization pathway involves γ -glutamylated intermediates of *Escherichia coli* K-12. *J. Biol. Chem.*, **2005**, 280, 4602-4608.
- [7] Kurihara, S.; Oda, S.; Tsuboi, Y.; Kim, H.-G.; Oshida, M.; Kumagai, H.; Suzuki, H. γ -Glutamylputrescine synthetase in the putrescine utilization pathway of *Escherichia coli* K-12. *J. Biol. Chem.*, **2008**, 283, 19981-19990.
- [8] Jeitner, T.M.; Matson, W.R.; Folk, J.E.; Blass, J.P.; Cooper, A.J.L. Increased levels of γ -glutamylamines in Huntington disease CSF. *J. Neurochem.*, **2008**, 106, 37-44.
- [9] Andruszkiewicz, R.; Wojciechowska, H.; Borowski, E. Syntheses of edeine antibiotics and their analogs. 1. Synthesis of *N*-(3-amino-propyl)-*N,N'*-di-*t*-butyloxycarbonyl-L,4-diaminobutane. *Polish J. Chem.*, **1978**, 52, 1167-1172.
- [10] Gardner, R.A.; Kinkad, R.; Wang, C.; Phanstiel IV, O. Total synthesis of petrobactin and its homologues as potential growth stimuli for *Marinobacter hydrocarbonoclasticus*, an oil-degrading bacteria. *J. Org. Chem.*, **2004**, 69, 3530-3537.
- [11] Han, G.; Tamaki, M.; Hruby, V.J. Fast, efficient and selective deprotection of the *tert*-butoxycarbonyl (Boc) group using HCl/dioxane (4 M). *J. Peptide Res.*, **2001**, 58, 338-341.
- [12] Lochner, M.; Geneste, H.; Hesse, M. Allgemeiner Zugang zu Polyaminen mit Ethan-1,2-diamin-Einheiten: Synthese von nicht natürlich vorkommenden homologen und isomeren *N*¹,4-Di(4-cumaroyl)sperminen. *Helv. Chim. Acta*, **1998**, 81, 2270-2281.
- [13] Krapcho, A.P.; Kuell, C.S. Mono-protected diamines. *N*-*tert*-butoxycarbonyl- α,ω -alkanediamines from α,ω -alkanediamines. *Synth. Commun.*, **1990**, 20, 2559-2564.